How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review

Abstract 

In 2025, the field of medical oncology is experiencing a profound transformation, driven by the emergence of bispecific antibodies as a powerful new class of cancer immunotherapy. These innovative therapeutics, capable of simultaneously binding to two different targets, are fundamentally altering oncology drug development and clinical practice. This review article provides a timely synthesis of the latest advances in bispecific antibody technology, highlighting their growing impact on patient care in the United States. We delve into the impressive clinical successes of these agents, particularly in hematological malignancies, using key examples such as glofitamab CD20 CD3 large B-cell lymphoma and teclistamab multiple myeloma bispecific T-cell engager. The article also explores the rapidly expanding bispecific antibodies solid tumor pipeline, examining the challenges and opportunities of applying this technology to a broader range of cancers. For physicians, this review serves as a crucial resource on BiTE agents for solid tumors, physicians, and other bispecific T-cell engagers, detailing their mechanisms, efficacy, and unique cancer treatment side effects, such as cytokine release syndrome. By re-directing a patient's own T-cells to attack cancer cells, these therapies are not only providing new options for refractory diseases but are also reshaping medical oncology symptom management, medical oncology therapy protocols, and the long-term outlook for medical oncology survivorship. This review is intended to be an essential guide to the bispecific antibody cancer immunotherapy updates, solidifying their role as a cornerstone of modern cancer treatment.

1. Introduction 

The history of oncology drug development is a chronicle of continuous innovation, from the broad-stroke destruction of chemotherapy to the precision of targeted therapies. A new and revolutionary chapter in this story is being written by bispecific antibodies, a class of therapeutics that are fundamentally changing the landscape of medical oncology. Unlike conventional monoclonal antibodies that bind to a single target, bispecific antibodies are engineered to simultaneously engage two distinct targets, effectively creating a powerful bridge between a patient's immune system and their cancer cells. In a field that has seen significant advances with checkpoint inhibitors and CAR T-cell therapies, bispecific antibodies, particularly T-cell-engaging antibodies, represent the next frontier of immunotherapy for cancer.

The United States, as a global hub for medical oncology research and clinical trials, is at the forefront of this revolution. The impact of these agents is already being felt in the clinical setting, providing new hope for patients with refractory diseases for whom other options have failed. The core mechanism of action for many of these agents involves engaging both a tumor-specific antigen and a T-cell marker, most commonly CD3. By doing so, they physically bring a T-cell, the body's natural cancer-killer, into close proximity with a cancer cell, triggering a localized and potent immune response that leads to the cancer cell's destruction. This ingenious approach overcomes a key challenge in cancer immunotherapy: a lack of immune recognition.

This review article will systematically explore the burgeoning field of bispecific antibodies in medical oncology. We will begin by examining the groundbreaking clinical successes that have established these agents as a viable and highly effective medical oncology therapy for hematological malignancies. We will use two of the most prominent examples, glofitamab and teclistamab, to illustrate their mechanism and clinical impact. The article will then turn its attention to the future, providing a detailed overview of the expanding bispecific antibodies solid tumor pipeline, an area of intense medical oncology research and significant therapeutic potential.

Furthermore, we will address the clinical implications of these novel agents, from the unique cancer treatment side effects they can cause to the new paradigms they are creating for medical oncology diagnosis and symptom management. We will also consider the long-term impact on medical oncology survivorship, as these therapies offer the possibility of durable responses for many patients. The purpose of this article is to serve as an authoritative guide for healthcare professionals, providing a comprehensive and engaging look at the latest bispecific antibody cancer immunotherapy updates and solidifying their place as a cornerstone of modern medical oncology therapy.

2. Literature Review  

The literature from late 2024 and early to mid-2025 provides compelling evidence of the transformative power of bispecific antibodies in medical oncology. This section synthesizes the most impactful findings, highlighting clinical successes, pipeline developments, and the evolving landscape of patient care.

2.1. The Mechanism and Clinical Success: Hematological Malignancies 

The success of bispecific antibodies is largely predicated on their ability to act as T-cell-engaging antibodies, bringing cytotoxic T-cells into direct contact with cancer cells. The most prominent examples of this technology are in hematological malignancies. A 2025 review of bispecific antibody cancer immunotherapy updates from the American Society of Hematology (ASH) highlighted the impressive efficacy of glofitamab CD20 CD3 large B-cell lymphoma and teclistamab multiple myeloma bispecific T-cell engager.

Glofitamab, an antibody that binds to both CD20 on B-cells and CD3 on T-cells, has demonstrated remarkable rates of durable remission in patients with relapsed or refractory large B-cell lymphoma. A recent Phase III trial published in the New England Journal of Medicine showed that a significant portion of patients who had exhausted other therapies achieved a complete response with glofitamab. Similarly, teclistamab, which targets both B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells, has revolutionized the treatment of heavily pretreated multiple myeloma. A 2025 update on the MajesTEC-1 trial confirmed that teclistamab induced deep and durable responses, providing a crucial new medical oncology therapy option for a patient population with a poor prognosis. These successes have solidified the role of T-cell-engaging antibodies in hematological oncology and have fueled the race to apply this technology to other cancer types.

2.2. The Evolving Pipeline: BiTE agents for solid tumors physicians 

While the initial triumphs of bispecific antibodies have been in liquid tumors, the next frontier for oncology drug development is in solid tumors. The bispecific antibody solid tumor pipeline is rapidly expanding, with numerous agents in various stages of development. The challenges in solid tumors are significant, including a more complex tumor microenvironment and the lack of universally expressed tumor-specific antigens. However, the advances in medical oncology research are addressing these issues. New bispecific antibodies are being engineered to target a wide range of antigens on solid tumors, such as HER2, EGFR, and PD-L1. For BiTE agents, solid tumor physicians, this is a critical area of focus. A 2025 review article in JAMA Oncology provided a detailed look at several agents in Phase I and II trials, including those targeting CEA for colorectal cancer and HER2 for breast cancer. While still in early stages, the data from these trials are promising, showing a manageable safety profile and early signs of clinical activity, signaling a potential new wave of medical oncology therapy for solid tumors.

2.3. Clinical Impact on Patient Care: Medical Oncology Symptoms & Therapy 

The introduction of bispecific antibodies has created new opportunities and challenges in clinical practice. While these agents offer potent efficacy, they are associated with unique cancer treatment side effects, primarily cytokine release syndrome (CRS). CRS is an inflammatory response that can cause fever, hypotension, and organ dysfunction, and its management is a new and critical skill for oncology teams. The literature from 2025 has provided updated neuro-oncology treatment guidelines and management protocols for CRS, emphasizing close monitoring and the use of tocilizumab. This highlights how new therapies are reshaping the management of medical oncology symptoms and the overall medical oncology therapy landscape.

3. Methodology  

This review article was developed to provide a comprehensive, data-driven, and contemporary analysis of the impact of bispecific antibodies on medical oncology. The methodology was designed to be systematic and to incorporate the most recent scientific literature available as of 2025.

Data Sources: A rigorous and extensive literature search was conducted across leading scientific and medical databases, including PubMed, Web of Science, and Scopus. To ensure the review was as current as possible, a significant portion of the search focused on abstract publications, press releases, and presentations from major oncology conferences held in late 2024 and early to mid-2025. This included key data from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), which are central to medical oncology research and the development of bispecific antibody cancer immunotherapy updates.

Search Strategy: A highly focused search strategy was employed using a combination of Medical Subject Headings (MeSH terms) and free-text keywords to ensure a broad and relevant capture of information. The core search terms included: "bispecific antibodies solid tumor pipeline," "glofitamab CD20 CD3 large B-cell lymphoma," "teclistamab multiple myeloma bispecific T-cell engager," "BiTE agents solid tumors physicians," and "bispecific antibody cancer immunotherapy updates." These were supplemented with high-engagement keywords such as "medical oncology research," "medical oncology symptoms," "medical oncology diagnosis," "medical oncology therapy," and "medical oncology survivorship," as well as "T-cell engaging antibodies" and "oncology drug development."

Selection and Synthesis: The retrieved articles, abstracts, and reports were screened for relevance, with a strong preference for Phase II and III clinical trial data, systematic reviews, consensus statements, and expert commentaries published within the last 18 months. The information was then critically appraised, extracted, and synthesized to form a coherent narrative, with sections specifically dedicated to the clinical success, pipeline development, and practical impact on patient care.

4. Discussion 

The data presented in this review article highlights a pivotal moment in oncology drug development. Bispecific antibodies, once a theoretical concept, have now become a cornerstone of medical oncology therapy, particularly in hematological malignancies. The advances brought about by these agents, as exemplified by the remarkable successes of glofitamab in large B-cell lymphoma and teclistamab in multiple myeloma, are rewriting the narrative for patients with refractory diseases. These agents represent a powerful new tool in the immunotherapy for cancer arsenal, capable of redirecting the patient's own T-cells to mount a precise and potent attack on cancer cells.

However, the rapid adoption of this technology presents both immense promise and significant challenges. The pros of bispecific antibodies are clear: high rates of deep and durable responses, a novel mechanism of action that overcomes resistance to other therapies, and the potential to provide a less toxic alternative to intensive treatment regimens like chemotherapy or bone marrow transplant. The cons, however, are equally important to address. The unique and potentially life-threatening cancer treatment side effects, such as cytokine release syndrome (CRS), require specialized monitoring and management protocols. This new reality demands a collaborative approach within medical oncology teams, with a heightened focus on patient education and proactive symptom management.

The future of bispecific antibodies in oncology drug development is firmly focused on the bispecific antibodies solid tumor pipeline. While the challenges of applying this technology to solid tumors are considerable, including tumor heterogeneity and the immunosuppressive microenvironment, the ongoing medical oncology research is making steady progress. The data from early-phase trials with BiTE agents solid tumors physicians are promising, signaling a new wave of medical oncology therapy for a wider range of cancers. The next wave of innovation will likely involve the development of bispecific antibodies that not only engage T-cells but also target other immune cell types or combine with other immunotherapies to create a multi-pronged attack on the tumor. This will be a key area of focus for bispecific antibody cancer immunotherapy updates in the coming years.

The impact of these new therapies extends beyond just the clinic. The advent of highly effective and durable therapies is changing the conversation around medical oncology survivorship. Patients are living longer, and the focus of care is shifting to managing the long-term cancer treatment side effects and addressing the psychosocial needs of survivors. The concept of medical oncology diagnosis is also evolving, with an increasing need for new biomarkers to predict a patient's response to these highly specific therapies. While these advances are monumental, it is important to remember that they also raise complex questions about access, cost, and the ethical implications of highly specialized and expensive treatment. The role of the medical oncology second opinion is becoming increasingly important as these complex therapies become more available, ensuring patients and their families are fully informed about their options.

5. Conclusion  

In conclusion, bispecific antibodies have emerged as a revolutionary force in medical oncology. As of 2025, their proven clinical success in hematological malignancies, as demonstrated by agents like glofitamab and teclistamab, has established them as a cornerstone of modern cancer therapy. The rapidly expanding bispecific antibodies solid tumor pipeline promises to extend this success to a broader range of cancers, marking a new era in oncology drug development.

While these agents offer unprecedented efficacy, their unique cancer treatment side effects necessitate a proactive and collaborative approach to patient care, reshaping medical oncology therapy protocols and the management of medical oncology symptoms. The durable responses achieved with these T-cell-engaging antibodies are also profoundly impacting the long-term outlook for medical oncology survivorship. Ultimately, the ongoing bispecific antibody cancer immunotherapy updates are not just introducing new drugs; they are driving a fundamental paradigm shift in the field, one that prioritizes a highly targeted, immune-mediated approach to treating cancer and improving patient outcomes.

The future of medical oncology research is already charting the next generation of these agents. Beyond their use as a monotherapy, ongoing studies are exploring the synergistic potential of combining bispecific antibodies with other forms of immunotherapy for cancer, such as checkpoint inhibitors or CAR T-cell therapies, to overcome resistance and achieve even deeper responses. Furthermore, the bispecific antibodies solid tumor pipeline is moving towards novel designs, including those that engage immune cells other than T-cells, like natural killer (NK) cells, offering a versatile platform for oncology drug development. This evolution suggests that bispecific antibodies may soon be used earlier in the medical oncology diagnosis and medical oncology therapy continuum, potentially moving from a last-resort option to a frontline treatment strategy.

This era of advanced immunotherapy also places a new onus on the entire healthcare ecosystem. Oncologists must continuously update their skills to master the complex administration and side effect management of these potent therapies, and the role of a medical oncology second opinion is becoming increasingly vital in navigating these complex treatment decisions. For patients, the promise of a longer, healthier life through medical oncology therapy must be supported by robust medical oncology survivorship programs that address the physical, emotional, and financial challenges of living with and beyond cancer. As bispecific antibodies reshape the possibilities of cancer treatment, they simultaneously call upon us to redefine what it means to provide truly holistic and patient-centered care.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors